Narwhal Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Narwhal Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-16,890	Closed	-$612K	–	148
2016 Q4	$612K	Sell	16,890 -55,120	-77%	-$2.2M	0.18%	102
2016 Q3	$3.31M	Sell	72,010 -500	-0.7%	-$26.1K	1.04%	27
2016 Q2	$3.64M	Buy	72,510 +17,660	+32%	+$940K	1.14%	25
2016 Q1	$2.94M	Buy	54,850 +11,400	+26%	+$669K	0.96%	33
2015 Q4	$2.85M	Hold	43,450	–	–	0.99%	32
2015 Q3	$2.45M	Hold	43,450	–	–	0.92%	37
2015 Q2	$2.57M	Hold	43,450	–	–	0.93%	34
2015 Q1	$2.71M	Buy	43,450 +1,980	+5%	+$115K	0.99%	31
2014 Q4	$2.38M	Buy	41,470 +200	+0.5%	+$11.1K	0.92%	35
2014 Q3	$2.22M	Sell	41,270 -13,450	-25%	-$713K	0.89%	37
2014 Q2	$2.87M	Sell	54,720 -1,230	-2%	-$62.9K	1.1%	24
2014 Q1	$2.96M	Hold	55,950	–	–	1.23%	15
2013 Q4	$2.24M	Buy	55,950 +6,300	+13%	+$248K	0.92%	33
2013 Q3	$1.88M	Buy	49,650 +3,900	+9%	+$152K	0.9%	42
2013 Q2	$1.79M	Buy	+45,750	New	+$1.78M	0.87%	44

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Narwhal Capital Management's TEVA Position: Q1 2017 in Review

Narwhal Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 16,890 shares — an estimated $612K sold.

Narwhal Capital Management first reported a position in TEVA in Q2 2013 and held it in 15 quarters. The position peaked at $3.64M in Q2 2016. 687 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

Narwhal Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Narwhal Capital Management sold 16,890 Teva Pharmaceuticals shares in Q1 2017, an estimated $612K.
Narwhal Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 15 quarters.
Narwhal Capital Management's Teva Pharmaceuticals position peaked at $3.64M in Q2 2016.
687 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Narwhal Capital Management's 13F filing for Q1 2017, filed 26 Apr 2017.